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Abstract
Background: The importance of 2-yr postradiotherapy prostate biopsy status remains
uncertain.
Objective: To assess the value of 2 year post treatment biopsies in a randomised trial of
radiotherapy dose escalation.
Design, setting, and participants: Between 1998 and 2001, 843 men with localised
prostate cancer were randomised to receive either control-64 Gy or escalated-74 Gy
conformal radiotherapy (CFRT) in the MRC RT01 trial in combination with 3–6-mo
neoadjuvant androgen deprivation therapy. Prostate biopsies were planned at 2 yr from
start of CFRT in suitable men.
Outcome measurements and statistical analysis: Prostate biopsy results and prostate-
speciﬁc antigen (PSA) levels performed at 2 yr post-CFRT were evaluated with long-term
biochemical progression free survival (bPFS) and overall survival. Outcome measures
were timed from the 2-yr biopsy using a landmark approach.
Results and limitations: A 2-yr biopsy was performed in 312/843 patients. One hundred
and seventy-seven patients were included in the per-protocol group with median
follow-up of 7.8 yr from biopsy. Median PSA at biopsy was 0.5 ng/ml. Sixty-four bPFS
events were reported: 46/145 (32%) in patients with negative, 6/18 (33%) suspicious, and
12/14 (86%) positive biopsies. A positive biopsy was prognostic of worse bPFS, going
forward, compared with negative and suspicious biopsies, hazard ratio (HR) = 4.81 (95%
conﬁdence interval [CI]: 2.50–9.26, p < 0.001). The estimate for survival was HR = 1.58
(95% CI: 0.52–4.78, p = 0.42). PSA values at 2 yr between 1.01 ng/ml and 2.09 ng/ml were
also associated with subsequent PSA failures (HR = 2.71, 95% CI: 1.98–3.71), bPFS events
(HR = 2.45, 95% CI: 1.81–3.32), and prostate cancer-speciﬁc survival (HR = 2.87, 95% CI:
1.08–7.64) compared with PSA 1.0 ng/ml.
Conclusions: Two-year postradiotherapy prostate biopsies have limited value in
patients with PSA control but both positive biopsy and higher PSA status are strongly
associated with future bPFS events. A policy of selected biopsy may provide an oppor-
tunity for early salvage interventions.
Patient summary: Routine 2-yr postradiotherapy biopsy is not recommended but can
be considered in selected patients with unfavourable post-treatment prostate-speciﬁc
antigen levels who are suitable for early salvage treatments.oci© 2017 European Ass* Corresponding author. In
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There is controversy over the value of prostate biopsy after
radiotherapy (RT) treatment for prostate cancer in predict-
ing future survival and recurrence trends [1,2]. The inherent
difficulties in interpreting postradiation prostate biopsies
[3] and debate regarding the optimal time of performing
those biopsies have contributed to the uncertainty [1,4].
Previous reports have suggested that men with a positive
biopsy post-RT have a much worse prognosis than those
with negative biopsies. However, most of these reports
included a small number of patients, short-term follow-up,
and heterogeneous methods of pathology reporting
[5–8]. Our study included a large, prospectively-recruited
cohort of patients participating in a randomised controlled
trial, with 10-yr follow-up and a single reference pathologist.
2. Materials and methods
2.1. Design of the RT01 trial and treatments
The design, objectives, patient eligibility criteria, treatment methods of
the RT01 trial have been detailed previously [9–11]. In brief, consenting
men with histologically conﬁrmed T1b–T3a N0 M0 prostate cancer and
prostate-speciﬁc antigen (PSA) levels <50 ng/ml were registered.
Patients having conformally-delivered radiotherapy were random-
ised to receive either a control schedule of 64 Gy/32f RT (Std-64 Gy) or an
escalated schedule of 74 Gy/37f (Esc-74 Gy). Neo-adjuvant androgen
deprivation therapy was administered 3–6 mo prior to RT and was
maintained until the end of RT. Based on pathology grading, PSA, and
T-stage, men were stratiﬁed into two groups according to the risk of
seminal vesicles involvement (low or moderate/high risk) [12].
The trial followed the principles of the Declaration of Helsinki. Each
centre attained ethical approval and participants gave separate informed
consent for trial participation and the 2-yr biopsy.
2.2. Trial assessments
2.2.1. Assessments
Before treatment each patient underwent a prostate biopsy, PSA
measurement, and local (digital rectal examination, transrectal ultra-
sound/magnetic resonance imaging [MRI]), lymph node (computed
tomography [CT]/MRI), and metastases staging (bone scan, chest x-ray).
PSA and digital rectal examination were performed post-RT (10 wk,
18 wk) and were repeated at 6 mo,12 mo,18 mo, and 24 mo, and annually
thereafter. Full assessment of the disease was undertaken if there was
clinical or biochemical evidence of disease recurrence, which included
CT or MRI of the pelvis and bone scan. Prostate biopsy was performed 2 yr
from start of RT in consenting patients without evidence of biochemical
or clinical progression. This entailed transrectal two to four core biopsies
or more if clinically indicated.
2.2.2. Two-year biopsy review
The window for the 2-yr biopsy was determined retrospectively as 18–36
mo after starting RT. These biopsies were reviewed by local and central
pathologists. The biopsy outcomes at central review were classiﬁed as:
(1) positive, if haematoxylin and eosin staining showed evidence of
residual malignancy, regardless of the scarcity of malignant cells, (b)
negative, if no malignant cells were present, or (c) suspicious, if it was not
possible to distinguish cancerous cells from radiation atypia, even after
immunostaining (CK-34beta-E12) or PSA staining.Please cite this article in press as: Kass-Iliyya A, et al. Two-years Po
(2018), https://doi.org/10.1016/j.eururo.2017.12.0172.2.3. Definition of biochemical failure and assessment of
progression
Biochemical failure was considered to have occurred if both of two
conditions were met in close accord with the Phoenix deﬁnition [10]: (1)
PSA >2 ng/ml measured 6 mo after RT commenced and (2) rise in PSA
from nadir level by 50%. Full re-evaluation of disease (CT/MRI/bone
scan) was triggered if there was clinical or biochemical evidence of
recurrence (trigger values: PSA  10 ng/ml and 50% of presenting PSA
level) [13].
2.3. Outcome measures
The coprimary outcome measures in RT01 were survival and
biochemical progression-free survival (bPFS). Survival was deﬁned as
time to death from any cause or censoring at date of last contact, bPFS
as time to the ﬁrst of: biochemical failure, death from prostate
cancer, or development of local, nodal, metastatic disease, or date of
last contact.
2.4. Analysis populations
2.4.1. Per-protocol group
This is the main focus of this analysis. The per-protocol group (PPG)
included only patients without a prior bPFS event who had 2-yr biopsy
within the window and which was reviewed centrally. Exclusion criteria
were: (1) bPFS event before or at biopsy and (2) biopsies performed
outside the 18–36 mo window. Analyses were timed from the 2-yr
biopsy.
2.4.2. Local histopathology review 2-yr biopsy group
This included patients without a prior bPFS event who had 2-yr biopsy
which was reviewed locally (with or without central review). The same
exclusion criteria applied as for the PPG. Analyses were timed from the 2-
yr biopsy.
2.4.3. Exploratory group
This included only patients with a bPFS event at or before the 2-yr biopsy.
Analyses were timed from randomisation.
2.4.4. Two-year PSA group
This included all patients with a PSA value within 20–28 mo after
randomisation (whether biopsied or unbiopsied), who were bPFS-event-
free up to the point of the 2-yr PSA test, and with PSA <2 ng/ml at the
time of the test. All outcome measures were timed from the date of 2-yr
PSA test.
2.5. Statistical considerations
Kaplan-Meier plots and log-rank test were used to study the impact of
the biopsy outcome on bPFS and survival. Cox models adjusted for
seminal vesicle involvement risk group and allocated treatment were
used to estimate the hazard ratio (HR).
Multivariate Cox proportional hazards models were applied to bPFS
and overall survival, using backward selection. Covariates were kept in
the ﬁnal model if they were statistically signiﬁcant at a level of
p < 0.10. Multiple logistic regression was used to study the impact of
covariates on the outcome of the biopsy. Negative and suspicious
outcomes were grouped together since there was no evidence of a
difference for each outcome measures using log-rank test.
Kappa statistic was used to determine agreement between the local
and central review. Fisher's exact test was applied to test the association
between the seminal vesicle (SV) involvement and outcome of the
biopsy. All analyses used a two-sided 5% signiﬁcance level.stradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol
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Data were frozen on August 2, 2011, matching the previous
results paper [10].
3.1. Patient populations
Of the 843 men randomised in RT01, 312 men (37%)
underwent a 2-yr biopsy of the prostate. Median time from
starting RT to biopsy was 2.1 yr (interquartile range: 2.0–
2.2). Three hundred and eleven out of 312 (99.7%) biopsies
were reviewed locally and 223/312 (71%) were reviewed
centrally.
Seventy out of 312 (22%) patients were excluded from the
PPG, mainly (65/70) because a bPFS event was reported
before or on the date of 2-yr biopsy (Fig. 1).
In the remaining 242 patients (local histopathology
review 2-yr biopsy group [LBG]), biopsy outcomes were:
negative 198/242 (82%), suspicious 19/242 (8%), and
positive 25/242 (10%). The PPG consists of 177 patients
whose biopsy outcomes were negative 145/177 (82%),
suspicious 18/177 (10%), and positive 14/177 (8%). Kappa
statistic showed good agreement between local and central
pathologists assessments (kappa = 0.71; Table 1) [14].
3.2. PPG analyses (N = 177)
3.2.1. Baseline characteristics
The median age, Gleason score. and SV involvement risk
groups of 177 patients in PPG were similar to the main trial
population (Table 2).
A similar proportion of the Std-64 Gy group were
included in the PPG biopsy cohort (93/421; 22%) as the
Esc-74 Gy group (84/422; 20%) but biopsy-positive
rates were lower in Esc–74 Gy (3/84; 4%) than Std-64 Gy
(11/93; 12%).
In a multivariate analysis (logistic regression), consider-
ing age, T-stage, Gleason score, pretreatment PSA, SV
involvement risk group, and allocated treatment, the
strongest associations with biopsy outcome were PSA
value, as a continuous measure, at 2 yr (odds ratio [OR]
= 1.90, 95% confidence interval [CI]: 0.97–3.71, p = 0.06),
allocated treatment (OR = 0.31, 95% CI: 0.08–1.24, p = 0.10),
and SV involvement risk group (OR = 2.61, 95% CI: 0.44–
15.31, p = 0.29) but none of these reached statistical
significance (Supplementary Table 1).
3.2.2. bPFS
Sixty-four bPFS events were reported in the PPG: 46/145
(32%) in patients with negative, 6/18 (33%) suspicious, and
12/14 (86%) positive biopsies, respectively. Patients with a
positive biopsy were more likely to report a bPFS event in
the future (HR = 4.81, 95% CI: 2.50–9.26, p < 0.001; Fig. 2A,
Table 3).
The strongest associations with bPFS events on multi-
variate analysis were the outcome of the 2-yr biopsy
(HR = 4.82, 95% CI: 2.53–9.19, p < 0.001), PSA at 2-yr
(HR = 1.47, 95% CI: 1.20–1.81, p < 0.001), and T3 stage
(HR = 1.87, 95% CI: 1.03–3.40, p = 0.04).Please cite this article in press as: Kass-Iliyya A, et al. Two-years Pos
(2018), https://doi.org/10.1016/j.eururo.2017.12.017Notably, 2/14 (14%) patients with positive prostate
biopsies at 2-yr had no evidence of bPFS or clinical failure
after completing 10-yr follow-up. Two-year PSA levels were
0.1 ng/ml and 0.2 ng/ml.
3.2.3. Overall survival and prostate cancer-specific survival
Twenty-seven deaths were reported: 21/145 (14%) in
patients with negative, 2/18 (11%) suspicious, and 4/14
(29%) positive biopsies, respectively (Figs. 2E and F2F).
There was no statistically significant increased risk of death
from any cause in patients with positive compared
with suspicious or negative biopsies: HR = 1.58 (95% CI:
0.52–4.78, p = 0.42). Only 4/27 deaths were attributed to
prostate cancer: 1/145 in patients with negative, 0/18
suspicious, and 3/14 positive biopsies, respectively:
HR = 15.64 (95% CI: 1.41–173.66, p = 0.02).
3.3. LBG analyses (N = 242)
3.3.1. Baseline characteristics
The median age, Gleason score, and SV involvement risk
groups of the 311 LBG patients were similar to the main trial
population (Supplementary Table 2).
3.3.2. All outcome measures: results
Survival and bPFS results in the LBG group are broadly
consistent with the PPG (Supplementary Table 3, Fig. 1), for
example, for bPFS (HR = 1.64, 95% CI: 0.90–2.97, p < 0.001).
Of the 37 deaths, only six (16%) were attributed to prostate
cancer. Comparison of positive versus negative and suspi-
cious biopsies in terms of prostate cancer-specific survival
(PCSS) gave HR = 9.77 (95% CI: 1.61–59.20, p = 0.01). The
strongest associations with bPFS were PSA 1 ng/ml at 2-yr
(HR = 1.54, 95% CI: 1.30–1.83, p < 0.001) and T3 stage
(HR = 1.97, 95% CI: 1.17–3.33, p = 0.01).
3.4. Exploratory group (early failures, N = 65)
This consists of 65 patients who had a bPFS event before or
on the date of their 2-yr prostate biopsy. Forty-six out of
65 of these biopsies were centrally reviewed. A higher
proportion of these patients had a positive biopsy (19/46
[41%]) than the PPG (14/177 [13%]). There was an imbalance
between the randomised groups with 32 (69%) of patients
treated with 64 Gy and 13 (31%) treated with 74 Gy with
biopsy positivity rates of 50% and 25%, respectively.
3.5. Overall death and prostate cancer-specific mortality
comparing biopsied and nonbiopsied patients
The death rate was higher in the nonbiopsied patients; only
20.5% (64/312) of biopsied patients died compared with 32%
(172/531) in the nonbiopsied group. Seventy patients were
excluded from the LBG population, and 65/70 were
excluded due to bPFS before 2 yr (the exploratory group
[EG]). The death rate was much higher in this subgroup: 39%
(27/70). Prostate cancer mortality was similar and low in
the biopsied and unbiopsied populations who had PSA/
clinical control at 2 yr with 6/242 (2%) and 19/448 (4%)tradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol
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-1  not reviewed locally nor centrally
-2 biopsy too early (< 18 m from start of RT)
-4  biopsy too late (> 36 m aer start of RT)
19 not randomised
65 excluded
Biopsy not reviewed centrally
Fig. 1 – CONSORT diagram.
bPFS = biochemical progression-free survival; LB = local histopathology review 2-yr biopsy; MFS = metastasis-free survival; OS = overall survival;
PCa = prostate cancer; RT = radiotherapy.
a 1 patient satisfies both criteria.
b 1 patient satisfies both criteria.
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patients who had PSA/clinical failure by 2 yr with 24% (17/
70) and 59% (49/83) prostate cancer deaths in biopsied and
unbiopsied cohorts, respectively (Supplementary Table 5).Table 1 – Agreement between local and reference histopathologist
assessments
Reference histopathologist
Local
histopathologist
Negative Suspicious Positive Not done Total
Negative 153 6 0 65 224
Suspicious 7 13 4 5 29
Positive 3 8 29 18 58
Not done 0 0 0 1 1
Total 163 27 33 89 312a
a Biopsy was performed in 312/843 patients.
Please cite this article in press as: Kass-Iliyya A, et al. Two-years Po
(2018), https://doi.org/10.1016/j.eururo.2017.12.0173.6. Prognostic value of PSA at 2 yr
This can only be assessed in patients who had not previously
reported a bPFS event and for whom a 2-yr PSA value was
available: this was 621/843 (74%) patients.
3.6.1. Two-year PSA and centrally-reviewed biopsies
Within these 621 patients, 2-yr biopsies had been
performed in 251 (40%), with a central biopsy review in
179/251 (71%) patients. In these 179 patients, there was an
association between higher 2-yr PSA values and positive
biopsy (Fisher's test, p < 0.001); 11/31 (35%) patients with
2-yr PSA of 1.01–2 ng/ml had a positive biopsy on central
review, compared with 10/148 (7%) with PSA <1 ng/ml. The
median 2-yr PSA value was 0.5 ng/ml and, splitting at this
point, positive biopsies were seen on central review for 9/95
(9%) patients with 2-yr PSA 0.5 ng/ml, 0/48 with PSA
0.51–0.99 ng/ml (0%) and 12/36 (33%) with PSA 1–2 ng/ml.stradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol
Table 2 – Baseline patient and tumour characteristics, by inclusion into per-protocol group (central review)
Per-protocol group All other patientsa
Negative Suspicious Positive
N (%) N (%) N (%)
Age (yr)
Median (IQR) 69 (65–72) 70 (66–72) 67 (63–71) 67 (63–71)
Mean 68 68 66 67
Range 47–80 58–76 51–74 47–81
T stage
T1b–T2a 107 (74) 10 (56) 8 (57) 375 (57)
T2b 19 (13) 4 (56) 3 (21) 158 (24)
T3 19 (13) 4 (22) 3 (21) 121 (19)
Not known 0 (NA) 0 (NA) 0 (NA) 12 (NA)
Imputed Gleason score
6 96 (66) 11 (91) 9 (64) 394 (60)
7 31 (21%0 7 (39) 4 (29) 180 (27)
8 18 (12) 0 (0) 1 (7) 87 (13)
Not known 0 (NA) 0 (NA) 0 (NA) 5 (NA)
PSA (ng/ml)
Median (IQR) 10.0 (6.7–15.4) 11.6 (8.1–13.9) 15.0 (10.7–19.1) 13.4 (8.4–21.4)
Mean (SD) 12.7 (8.5) 13.5 (10.2) 15.0 (6.1) 16.0 (10.0)
Seminal vesicle risk groupb
Low 62 (43) 10 (56) 3 (21) 200 (30)
Moderate/high 83 (57) 8 (44) 11 (79) 466 (70)
Allocated treatment
Std-64Gy 70 (48) 12 (67) 11 (79) 328 (49)
Esc-74Gy 75 (52) 6 (33) 3 (21) 338 (51)
Total 145 18 14 666
Esc-74 Gy = escalated 74 Gy; IQR = interquartile range; NA = not applicable; PSA = prostate-speciﬁc antigen; SD = standard deviation; Std-64 Gy = standard
64 Gy.
a Biopsy not performed (N = 531, patient did not meet the criteria for inclusion in per-protocol group (N = 70; Fig. 1), biopsy not reviewed by reference pathologist
(N = 65).
b See Diaz et al [12].
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yr PSA was associated with subsequent PSA failures
(HR = 2.71, 95% CI: 1.98–3.71), bPFS events (HR = 2.45,
95% CI: 1.81–3.32), PCSS (HR: 2.87, 95% CI: 1.08–7.64), but
not clearly on metastasis-free survival (HR = 1.76, 95% CI:
0.86–3.60) or overall survival (HR = 0.95, 95% CI: 0.60, 1.51;
Fig. 3, Supplementary Table 4).
4. Discussion
Failure to eradicate local tumours correlates with distant
metastases development, cancer-related death, and overall
survival [15,16] and presently, post-RT prostate biopsy
remains the only direct measure of local tumour control
[17]. In agreement with other studies [4,15,16,18,19], our
results show that prostate biopsies performed between
18 mo and 36 mo after RT are highly prognostic of future
biochemical failure and disease–free status at 10 yr. As
reported in previous studies, we found similar prognostic
value for indeterminate and negative biopsies for subse-
quent biochemical failure [15,17,18,20].
We recognise the low positive biopsy rate in our study
[15,17]. In particular, the differences between our study and
RTOG 9408 which reported a 30% positive biopsy rate are of
interest [19]. Potential causes for our lower biopsy positive
rate include the use of dose escalation in 50% of the patients
who had a considerably lower rate of positive biopsiesPlease cite this article in press as: Kass-Iliyya A, et al. Two-years Pos
(2018), https://doi.org/10.1016/j.eururo.2017.12.017(74 Gy 4% vs 64 Gy 12%), the use of 6 mo rather than 4 mo
androgen suppression, and the strict exclusion of patients
who had PSA failure at the 2-yr time point. In our EG who
had PSA failure before or on the date of their 2-yr biopsy,
41% had positive biopsies. Finally, our study used two to four
biopsies and a higher positive biopsy rate might have been
found if more comprehensive prostate sampling had been
employed particularly if using MRI guidance.
We previously reported that 39% (91/236) of deaths in
the RT01 trial were due to prostate cancer [10] and PCSS is a
more appropriate outcome measure for assessing the value
of positive prostate biopsies than overall survival. We
observed significantly poorer PCSS in patients with positive
2-yr biopsies with HR of 15.6 and 9.8 in the PPG and LPG
groups, respectively; however, our evidence is limited due
to the small number of deaths (4/27 in PPG group), which
probably relates to case selection for biopsy excluding
patients with early PSA failure. Nevertheless, the data is in
accord with Zelefsky et al [15] who demonstrated a three-
fold increase in the rate of deaths from prostate cancer after
10-yr follow-up after a positive biopsy in intermediate- or
high-risk prostate cancer patients treated with RT.
We noted that early biochemical failure correlates with a
higher positive biopsy rate when compared with the
general PPG; this could be attributed to early local
recurrence reflecting more aggressive tumours. We also
observed that biochemical failure does not always correlatetradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol
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Fig. 2 – Outcome measures, per-protocol (PP) group (central review). (A) Biochemical progression-free survival (bPFS), by biopsy outcome. (B) bPFS,
negative and suspicious versus positive biopsy. (C) Metastases-free survival (MFS), by biopsy outcome. (D) MFS, negative and suspicious versus positive
biopsy. (E) Overall survival (OS), by biopsy outcome. (F) OS, negative and suspicious vs positive biopsy.
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biochemical failure in the EG had negative biopsies. This
is probably due to the development of extra-prostatic
recurrence as the cause of PSA failure or alternatively
missing the recurrent focus of tumour during biopsy,
yielding false-negative results.Please cite this article in press as: Kass-Iliyya A, et al. Two-years Po
(2018), https://doi.org/10.1016/j.eururo.2017.12.017PSA values at 2 yr were significantly correlated with
biopsy outcomes, bPFS, PCSS, with PSA >1 ng/ml associated
with a 2.7 higher chance of future biochemical failure than
PSA 1 ng/ml. This is in agreement with previous studies
reporting the importance of PSA nadir in predicting
biochemical failure and disease-free survival [21–24].stradiotherapy Biopsies: Lessons from MRC RT01 Trial. Eur Urol
Table 3 – Outcome measures, per-protocol group (central review)
Negative or suspicious biopsy Positive biopsy
Outcome measurea HRb (95% CI) p value Events/patients Events/patients
Biochemical progression-free survival 4.81 (2.50–9.26) <0.001 52/163 12/14
Metastases-free survival 1.97 (0.49–7.92) 0.34 9/163 3/14
Overall survival 1.58 (0.52–4.78) 0.42 23/163 4/14
Prostate cancer deaths 15.64 (1.41–173.66) 0.02 1/163 3/14
CI = conﬁdence interval; HR = hazard ratio.
a Timed from 2-yr biopsy.
b HR comparing “positive” versus “negative or suspicious” biopsy outcome, adjusted for seminal vesicle involvement risk group and allocated treatment.
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Fig. 3 – Time from 2-yr prostate-specific antigen (PSA) test to (A) PSA failure, (B) biochemical progression-free survival (bPFS) event, (c) metastasis-free
survival (MFS) event, (D) prostate cancer (PC)-related death, (E) death; 2-yr PSA population.
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procedure with risk of infection and bleeding. The uptake of
biopsies in this study was modest with only 37% compli-
ance. However, this is quite similar to the RTOG 9408 study
where 42% of patients were biopsied [19] suggesting that
this is the realistic proportion of patients who are likely to
be suitable and consent to biopsy in such large multi-centre
randomised trials. The timing of post-treatment biopsies is
problematic and false-positive results occur. Crook et al [4]
demonstrated that 30% of initially indeterminate biopsies at
13 mo cleared at a mean time of 31.6 mo; this is thought to
be secondary to the prolonged killing effect of RT. In this
series, two patients had positive biopsies at 2 yr with no
evidence of biochemical recurrence 10 yr following RT.
Conversely, sampling errors may lead to potential false-
negative results.
Pathology interpretation is not straightforward and
different assessment methods have been proposed
[16,21]. In this series, 27% (11/40) of biopsies scored positive
by local pathologists were downgraded to indeterminate or
negative
Since this study multiparametric MRI (mpMRI) of the
prostate has become an increasingly reliable method to
diagnose loco-regional and distant recurrence combining
T2 with diffusion weighted imaging [25,26]. One recent
study comparing mpMRI with histopathology after salvage
prostatectomy post-RT showed 50–71% sensitivity with 80–
100% specificity for detecting extra-prostatic extension
[27]. A further study reported an area under the curve of
0.84 when using mpMRI to detect local recurrence
compared with template transperineal biopsies [28]. Early
results assessing prostate-specific membrane antigen-
positron emission tomography appear promising [29].
Despite the association of positive post-RT prostate
biopsies with future bPFS and CSS, we would not
recommend routine biopsy in line with current practice
in the UK. Biopsy remains essential in selected patients led
by unfavourable post-treatment PSA profiles combined
with MRI in patients suitable and favouring local salvage
treatment. Clarification of the role of imaging and biopsy in
patients with post-treatment PSA levels 1.0–2.0 ng/ml
would be of value. For both the poor prognostic group of
patients with PSA failure before 2 yr and an intermediate
group with PSA levels 1–2 ng/ml at 2 yr imaging reassess-
ment might be considered. Prostate biopsy would only be
indicated after exclusion of extra-pelvic disease and there
should be MRI or other imaging evidence of locally
persistent disease. The patient must be suitable for and
want local salvage treatment. For the good prognosis group
of patients with PSA level of 1 ng/ml, the recurrence rate is
low with excellent long-term outcomes and we would not
recommend biopsy.
5. Conclusions
Prostate biopsies performed 2 yr after radical RT using
contemporary doses with neoadjuvant androgen depriva-
tion therapy are rarely positive in patients with PSA 2 ng/
ml but are associated with poor outcome. PSA failure withinPlease cite this article in press as: Kass-Iliyya A, et al. Two-years Po
(2018), https://doi.org/10.1016/j.eururo.2017.12.0172 yr of RT identifies a population at high risk of death from
prostate cancer. PSA-led prostate biopsies post-treatment
should be considered in selected patients suitable for local
salvage procedures.
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